The ADC ARX788 is a dolastatin analog (MMAF) that is coupled via a noncleavable linker to the HER2 IgG, with a mean drug-antibody ratio of 1.9, and has shown activity against HER2+ ovarian, gastric, and breast cancer cell lines50. Here, ERBB2 is linked to breast cancer.